ChemAxon has announced that Boehringer Ingelheim has chosen its chemistry software platform for multiple applications across research and development, supporting in-house activities and work with external collaboration partners.
ChemAxon technology will be used to store, search, calculate, and visualize chemical entities, properties and reactions, helping to streamline the progression from drug discovery to clinical candidate.
ChemAxon was chosen after an extensive evaluation process that built on dimensions such as ROI, performance, robustness, scalability and future development roadmap.
ChemAxon sets the standard in chemically-intelligent software for pharmaceutical R&D.
With a client list that includes all of the top 15 global pharma companies, the company continues to experience significant growth year on year.
Commenting on the agreement, Alex Drijver, CEO of ChemAxon said, “The adoption of ChemAxon technology by Boehringer Ingelheim further underlines our position as the platform of choice for R&D organizations planning their next-generation systems.”